Compare BMM & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMM | VALN |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | Canada | France |
| Employees | 68 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 545.3M | 495.5M |
| IPO Year | N/A | 2021 |
| Metric | BMM | VALN |
|---|---|---|
| Price | $4.87 | $7.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 214.4K | 26.9K |
| Earning Date | 05-25-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $4.75 |
| 52 Week High | $8.63 | $12.25 |
| Indicator | BMM | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 36.46 | 85.11 |
| Support Level | $4.85 | $5.03 |
| Resistance Level | $6.53 | $9.56 |
| Average True Range (ATR) | 0.44 | 0.19 |
| MACD | -0.02 | 0.18 |
| Stochastic Oscillator | 22.47 | 92.05 |
Blue Moon Metals Inc is a Canadian exploration stage company focused on the exploration and development of mineral resource properties. The company is advancing its Blue Moon polymetallic deposit which contains zinc, gold, silver, and copper. The projects of the company include the Nussir copper-gold-silver property in Norway (the "Nussir Property"), the Blue Moon zinc-copper-gold-silver property in California, USA (the "Blue Moon Property"), the NSG copper-zinc-gold-silver property in Norway (the "NSG Property") the Springer tungsten-molybdenum project in the Nevada, USA (the "Springer Property") and the Apex germanium-gallium-copper project in Utah, USA (the "APEX Property").
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.